ESMO 2016: Press & Media

Press Releases from the ESMO 2016 Congress

Filter

Date Title Topic
09 Oct 2016 ESMO 2016 Press Release: Nintedanib Improves Progression-free Survival but not Overall Survival in Phase III Trial of Metastatic Colorectal Cancer Gastrointestinal cancers
08 Oct 2016 ESMO 2016 Press Release: 70% of Advanced Cancer Patients Receive Palliative Care Consultation at ESMO Designated Centres Palliative and supportive care
08 Oct 2016 ESMO 2016 Press Release: True Burden of Head and Neck Cancer in France Underestimated by More Than One-Third Head and neck cancers
08 Oct 2016 ESMO 2016 Press Release: Ribociclib Improves Progression-free Survival in Advanced Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
08 Oct 2016 ESMO 2016 Press Release: Targeting Estrogen Receptor Improves Progression-free Survival in Advanced Breast Cancer Breast cancer - Anticancer agents & Biologic therapy
08 Oct 2016 ESMO 2016 Press Release: Immunotherapy Shows Promising Results in First and Second Line Treatment of Metastatic Bladder Cancer Genitourinary cancers - Anticancer agents & Biologic therapy
08 Oct 2016 ESMO 2016 Press Release: Ipilimumab as Adjuvant Therapy Improves Overall Survival in High Risk Stage III Melanoma Melanoma and other skin tumours
08 Oct 2016 ESMO 2016 Press Release: Niraparib Significantly Improves Outcome of Ovarian Cancer Patients in Landmark Trial Gynaecologic malignancies
08 Oct 2016 ESMO 2016 Press Release: Phase I Study of Novel Anti-Cancer Drug Uses Tumour mRNA Expression to Identify Responders Anticancer agents & Biologic therapy
07 Oct 2016 ESMO 2016 Press Release: Thousands of Melanoma Patients in Europe Have no Access to New Life Saving Drugs Melanoma and other skin tumours
07 Oct 2016 ESMO 2016 Press Release: Neoadjuvant Immunotherapy Prior to Surgery is Safe and Feasible in Early Lung Cancer Lung and other thoracic tumours - Cancer Immunology and Immunotherapy
07 Oct 2016 ESMO 2016 Press Release: High response rate in phase I/II paediatric brain cancer trial sets stage for combination therapy with higher response and lower toxicity Central nervous system malignancies
06 Oct 2016 ESMO 2016 Press Release: Improving Cancer Screening Participation Should be a Priority Epidemiology/Etiology/Cancer Prevention
05 Oct 2016 ESMO 2016 Press Release: Reporting of Adverse Events in Targeted Therapy and Immunotherapy Trials is “Suboptimal” Cancer Immunology and Immunotherapy - Anticancer agents & Biologic therapy
04 Oct 2016 ESMO 2016 Press Release: Impact of Cognitive Functions on Oral Cancer Therapies